NCT00501826 : Clinical Trial Detail - Cancer Knowledgebase (CKB)

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT00501826
Title	Combination Chemotherapy and Nelarabine in Treating Patients With T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
Recruitment	Recruiting
Gender	both
Phase	Phase II
Variant Requirements	No
Sponsors	M.D. Anderson Cancer Center
Indications	lymphoblastic lymphoma
Therapies	Nelarabine + Pegaspargase + Venetoclax Cyclophosphamide + Dexamethasone + Doxorubicin + Nelarabine + Pegaspargase + Venetoclax + Vincristine Sulfate Mercaptopurine + Methotrexate + Prednisone + Venetoclax + Vincristine Sulfate Cytarabine + Methotrexate + Nelarabine + Pegaspargase + Venetoclax Methotrexate + Pegaspargase + Venetoclax
Age Groups:	adult \| child \| senior
Covered Countries	USA

Facility	Status	City	State	Zip	Country	Details
M D Anderson Cancer Center	RECRUITING	Houston	Texas	77030	United States	Details

*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field

NCT00501826Clinical Trial Detail